Overview
To prospectively identify cancer patients whose tumors express specific molecular markers targeted by therapeutic agents from a comprehensive molecular test, for the purpose of selecting the most clinically appropriate treatment in a pragmatic two arm trial.
Eligibility
Inclusion Criteria:
- Patients who have given informed consent in accordance with the methods and procedures of this study
- Diagnosis of cancer (stage 3 and stage 4; solid tumors only) requiring medical care
- Patients who have not received treatment related to his/her cancer
- Patients who are willing to sign a release of medical records to the research team
- Male and female patients ≥18 years of age
- Patients under oncology care of a participating site
- Sufficient clinical status for collection of biospecimen samples within usual care
- Patients who have insurance coverage for CMT
Exclusion Criteria:
- Patients considered minors in the jurisdiction where the protocol is conducted.
- Patients who are prisoners and pregnant women.
- Patients who cannot provide consent and did not sign a power of attorney.